Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

UPDATE: Arrowhead Research (ARWR) PT Raised to $33 at Piper JaffrayApril 15, 2019 4:58 PM Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseApril 15, 2019 7:30 AM